Drug Safety Warnings and Updates: July-September 2017

Teresa Rubio, PharmD


January 03, 2018

Editorial Collaboration

Medscape &

In This Article

Metoclopramide hydrochloride (Reglan)

For more on this Drug Safety Labeling Change, click here.

For full prescribing information, click here.

Updated Boxed Warning


Reglan can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. There is no known treatment for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage.

Discontinue Reglan in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after Reglan is stopped.

Avoid treatment with Reglan for longer than 12 weeks because of the increased risk of developing TD with longer-term use.